Sarep­ta shakes up C-suite as they pre­pare to test FDA on Duchenne again

Af­ter slow­ly los­ing ex­ec­u­tives over the last two years, Sarep­ta has an­nounced a host of changes at its high­est lev­el.

Sarep­ta on Mon­day an­nounced a new CFO, chief com­mer­cial of­fi­cer, CSO and gen­er­al coun­sel, ef­fec­tive­ly giv­ing the biotech a new C-suite in a sin­gle press re­lease.

Sud­den and sweep­ing ex­ec­u­tive changes aren’t gen­er­al­ly a great in­di­ca­tor for a com­pa­ny’s health, but the cir­cum­stances around Sarep­ta’s lat­est changes are rel­a­tive­ly unique. The com­pa­ny hasn’t had a CSO since 2018, when Guriq Basi de­part­ed af­ter a one-year tenure. Their long­time chief com­mer­cial of­fi­cer, Bo Cum­bo, re­cent­ly spun out on his own, rais­ing $107 mil­lion for a new gene ther­a­py play. And their long­time CFO and CBO Sandy Ma­hatme “re­tired” in June for what turned out to be an op­por­tu­ni­ty to help run Bob Nelsen’s $800 mil­lion start­up Re­silience.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER